Although the hypothesis of insult by inflammation preceding progressive fibrosis in diseases holds a lot of value, the specific aetiology and mechanisms of fibrosis manifesting in distinct organs remains uncertain. Coupled with inter individual variability, the challenges of running a successful clinical trial are significantly greater.
In this workshop, we will be:
Jeffrey Browning, Research Professor, Boston University
Maria Trojanowska, Professor, Medicine, Boston University
With better screens and better tools giving better outcomes, critically assessing molecular prognostic biomarkers of fibrosis can inform an arsenal of non-invasive techniques and innovate drug development.
This workshop will explore:
Rana Herro, Junior Faculty Instructor, La Jolla Institute for Allergy & Immunology
Fibrogenic cells are generated from tissue resident stromal progenitors. The transition between progenitors and fibrogenic cells is a potential therapeutic target as well as a mechanism whose study can reveal how fibrosis ensues and therefore how it can be prevented.
Key topics to be covered in this expert led session:
Michael Underhill, Professor, Department of Cellular & Physiological Sciences , University of British Columbia
Fabio Rossi, Professor in Medical Genetics, University of British Columbia
Dario Lemos, Instructor in Medicine (Harvard Medical School) and Associate Bioengineer (Brigham & Women's Hospital) ,